jetcityimage/iStock Editorial via Getty Images
U.K.-based biotech Alchemab on Tuesday announced a licensing agreement with Eli Lilly (NYSE:LLY) to jointly develop ATLX-1282, an early-stage therapeutic candidate targeting amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.
The deal is built on Alchemab’s existing collaboration to develop